Just caught something interesting about Teva Pharmaceutical Industries that's worth paying attention to if you're looking at healthcare investment opportunities right now.

So here's the thing — while everyone's talking about Eli Lilly and how pharma stocks have been performing, Teva's quietly been crushing it. The stock has literally doubled over the past year. That's not a small move. Most people don't realize this because the company's been making a pretty significant shift in how it operates.

Teva used to be known as a generic drug maker, right? Pretty unsexy business model. But they've been pivoting hard into specialty pharmaceuticals, and that's where the real story is. I was looking at their latest earnings — released back in January for Q4 2025 — and the numbers are actually solid. Revenue hit $4.7 billion, up 11% year-over-year. But here's what caught my eye: earnings per share came in at $0.96, which crushed analyst expectations of $0.64. That's a meaningful beat.

Now, there's a caveat. They got $500 million in milestone payments from Sanofi for a drug candidate called duvakitug (targeting ulcerative colitis and Crohn's disease), which inflated the numbers a bit. Strip that out and growth is more modest. But even so, the underlying transformation is real.

Their branded specialty drugs — Austedo, Ajovy, Uzedy — are generating serious revenue now and offsetting flat generics sales. This is the pivot that matters for healthcare investment thesis. Management's actually projecting duvakitug could hit $2-5 billion in peak annual sales eventually. Add in their other pipeline candidates and you're looking at over $10 billion in potential peak sales across the pipeline.

Here's what makes this interesting from a valuation perspective: Teva's currently trading at about 12.5x forward earnings based on 2026 forecasts. That's middle-to-lower range for pharma. Analysts are expecting EPS to dip 8.5% in 2026, but then jump 12.3% in 2027. If that acceleration actually happens, and if the market starts pricing in their specialty drug growth trajectory more aggressively, you could see real multiple expansion on top of earnings growth.

The thing about this healthcare investment is that most of the transformation hasn't fully priced in yet. You're not buying after a massive run-up based on fully realized expectations. You're buying into a story that's still unfolding. If their growth starts accelerating in 2027 like management suggests, shares could move significantly higher from here.

Not saying it's guaranteed, but if you've got a multiyear horizon and you're thinking about where to deploy capital in healthcare investment, this one deserves a closer look. The risk-reward setup feels reasonable at current prices.